Blood Advances · 2022 · 27 citations · 27 references
MedicineHematologyClinical Decision SupportClinical EpidemiologyHemostasisAnticoagulant TherapyAnticoagulation ManagementAnticoagulation TherapyThrombosisThrombosis ManagementThrombosis PreventionAntiplatelet DrugsBleedingClinical Risk PredictionClinical Risk ScoresCox RegressionExtended-duration AnticoagulationPrimary Outcome AnalysisThromboembolism Risk Prediction
No clinical prediction model has been specifically developed or validated to identify patients with unprovoked venous thromboembolism (VTE) who are at high risk of major bleeding during extended anticoagulation. In a prospective multinational cohort study of patients with unprovoked VTE receiving extended anticoagulation after completing ≥3 months of initial treatment, we derived a new clinical prediction model using a multivariable Cox regression model based on 22 prespecified candidate predictors for the primary outcome of major bleeding. This model was then compared with modified versions of 5 existing clinical scores. A total of 118 major bleeding events occurred in 2516 patients (annual risk, 1.7%; 95% confidence interval [CI], 1.4-2.1). The incidences of major bleeding events per 100 person-years in high-risk and non-high-risk patients, respectively, were 3.9 (95% CI, 3.0-5.1) and 1.1 (0.8-1.4) using the newly derived creatinine, hemoglobin, age, and use of antiplatelet agent (CHAP) model; 3.3 (2.6-4.1) and 1.0 (0.7-1.3) using modified ACCP score, 5.3 (0.6-19.2) and 1.7 (1.4-2.0) using modified RIETE score, 3.1 (2.3-3.9) and 1.1 (0.9-1.5) using modified VTE-BLEED score, 5.2 (3.3-7.8) and 1.5 (1.2-1.8) using modified HAS-BLED score, and 4.8 (1.3-12.4) and 1.7 (1.4-2.0) using modified outpatient bleeding index score. Modified versions of the ACCP, VTE-BLEED, and HAS-BLED scores help identify patients with unprovoked VTE who are at high risk of major bleeding and should be considered for discontinuation of anticoagulation after 3 to 6 months of initial treatment. The CHAP model may further improve estimation of bleeding risk by using continuous predictor variables, but external validation is required before its implementation in clinical practice.
27
Antithrombotic Therapy for VTE Disease
Clive Kearon, Elie A. Akl, Joseph Ornelas et al. · CHEST Journal · 2016 · 4.8K citations
Stavros Konstantinides, Guy Meyer, Cecilia Becattini et al. · European Heart Journal · 2019 · 4.8K citations · Full text
Gary S. Collins, Johannes B. Reitsma, Douglas G. Altman et al. · Annals of Internal Medicine · 2015 · 2.9K citations · Full text